Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer: A case report

Medicine (Baltimore). 2019 Apr;98(16):e15333. doi: 10.1097/MD.0000000000015333.

Abstract

Rationale: Small-cell lung cancer (SCLC) is a common pathological type of lung cancer, but appendiceal metastasis of SCLC was rare. At present, clinical studies on the maintenance therapy of SCLC have not reached a significant conclusion.

Patient concerns: We reported on a 52-year-old man who diagnosed as extensive stage SCLC with abdominal pain for 2 months, aggravated for 2 days.

Diagnoses: The patient was diagnosed with extensive-stage SCLC, relapsed with appendix metastasis after treatment by emergency abdominal surgery.

Interventions: The patient received systemic treatments, including surgery, bevacizumab in combination with chemotherapy and bevacizumab alone was continued as maintenance therapy.

Outcomes: The patient had an overall survival would more than 23 months, and he gained another 8 months of progression-free survival after first-line radiochemotherapy.

Lessons: Although SCLC appendix metastasis is rare, continuous anti-angiogenic therapy combined with bevacizumab maintenance therapy after surgical treatment can prolong survival.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Appendiceal Neoplasms / drug therapy
  • Appendiceal Neoplasms / secondary*
  • Appendiceal Neoplasms / surgery
  • Appendiceal Neoplasms / therapy
  • Bevacizumab / administration & dosage
  • Bevacizumab / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / surgery
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Small Cell Lung Carcinoma / drug therapy
  • Small Cell Lung Carcinoma / pathology*
  • Small Cell Lung Carcinoma / surgery
  • Small Cell Lung Carcinoma / therapy

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Bevacizumab